Search
China's innovative drug industry has entered a phase of incremental innovation, signifying its burgeoning international competitiveness. Having evolved beyond mere follow-up innovation, the industry is now transitioning from a reliance on "introduction and imitation" to a focus on "innovation output." Enhanced financing accessibility and an improving international landscape have paved the way for fresh investment prospects in CXO companies and upstream scientific research sectors. Investors are advised to adopt a balanced, dumbbell strategy, allocating funds judiciously while keeping a keen eye on pivotal academic conferences throughout the year in both dividend blue chips and innovative drugs, in order to seize lucrative investment opportunities.
-
C114 Communication Network -
Communication Home
